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SUMMARY
Gangliosides are a diverse class of glycolipids found in the plasma membrane of mammalian cells and are particularly abundant
in cells of the nervous system. Serum antibodies to gangliosides have been detected in various neurological disorders with some
evidence that they play a pathogenic role. In this study, we have investigated whether anti-ganglioside antibodies were elevated
in a group of patients with rheumatoid arthritis (RA) who developed peripheral neuropathy (PN). An ELISA technique was
used to test sera from 28 patients with RA and PN, 38 RA patients without PN and 20 normal controls for the presence of
IgG and IgM anti-GMl and sulphatide antibodies. The patients with RA and PN had higher pain scores (P < 0.005), more
extra-articular features (P < 0.05), higher erosive scores (P < 0.0001), lower haemoglobin (P < 0.005), higher ESR (/> < 0.001)
and were more often on disease-modifying drugs {P < 0.05). Twelve RA patients with PN (43%), but only two RA controls
(5%), had positive titres against one or more gangliosides {P < 0.001). The neurologic disability score (NDS) correlated with
RA duration (P < 0.05), and with levels of IgM anti-GMl (P < 0.001) and IgM anti-sulphatide (P < 0.05) antibodies. We
conclude that PN is more common in patients with severe rheumatoid disease, and a significant proportion have elevated levels
of anti-ganglioside antibodies.
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GANGLIOSIDES are a family of acidic glycolipids [1]
which are composed of lipid (ceramide) and
carbohydrate (oligosaccharide chain) moieties. Four
gangliosides, GM1, GDI a, GDlb and GTlb, are
especially abundant in the brain, while LM1 constitutes
the major ganglioside in peripheral nerves [2].
Sulphatide is the major acidic glycosphingolipid in
myelin, and in peripheral nerves it is found in
concentrations 100 times that of other gangliosides [3].
Gangliosides reside in the outer layer of the plasma
membrane where they may regulate diverse physiologi-
cal processes [4, 5], including neural cell function [6],
cell-cell recognition, cell adhesion and the activity of
enzymes such as protein kinase C and Na-K-ATPase.
They influence neurite outgrowth [7] and possess
neuroprotective functions. Previous studies have
demonstrated beneficial effects from ganglioside
administration in animal models of diabetes, leading to
recovery in nerve conduction velocity and maintenance
of axonal transport of cytoskeletal proteins [8]. In a
study of patients with diabetic peripheral neuropathy
(PN), ganglioside administration improved paraesthe-
siae and nerve conduction [9].
The abundance of gangliosides in the nervous system
and their extracellular location make them potential
antigenic targets in autoimmune neurological
disorders. Antibodies to gangliosides have been found
in a variety of neurological conditions, including
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multifocal motor neuropathy, distal and proximal
lower motor neuron syndromes, and occasionally in
Guillain-Barre syndrome and polymyositis [10]. The
pathogenicity of anti-ganglioside antibodies has been
suggested by the development of neuropathy and
motor conduction block when these antibodies were
injected in rabbits [11]. It has also been found that the
IgM anti-GMl antibodies react against the neuronal
membranes by binding to the GM1 ganglioside [12].
Peripheral nerve involvement in rheumatoid arthritis
(RA) can include compressive neuropathy, which is by
far the commonest, and vasculopathy, resulting in
distal sensory and combined sensorimotor neuropathy
in 1-18% of patients [13]. Although the underlying
pathology of rheumatoid neuropathy is not clear,
humoral mechanisms such as the deposition of immune
complexes and fixation of complement are thought to
be important factors.
Histological examination of sural nerves has
demonstrated deposition of IgG, IgM, complement
and fibrin in areas corresponding to those of fibrinoid
necrosis [14]. As far as we are aware, no previous
studies have examined the levels of anti-ganglioside
antibodies in patients with RA and peripheral
neuropathy.
In this study, we have investigated the prevalence of
anti-GMl and sulphatide antibodies in patients with
RA complicated by PN, and compared the results with
measures of rheumatoid disease activity and damage.
PATIENTS AND METHODS
Consecutive patients with RA defined according to
the ARA 1987 revised criteria [15], who were attending
a district general hospital out-patient rheumatology
© 1996 British Society for Rheumatology
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TABLE I
Demographic details and indices of disease activity and damage in
RA patients with and without peripheral neuropathy. Values given
with confidence limits are means ± S.D.
Male: female
Age (yr)
Clinical indices
Duration of RA (yr)
Extra-articular
vasculitis
Early morning stiffness (min)
Visual analogue score (mm)
Disease-modifying therapy
Lower limb operations
Laboratory indices
Haemoglobin (g/dl)
ESR (mm/h)
CRP (mg/1)
Rheumatoid factor
ANA
IgG (gm/1)
IgM (gm/1)
Larsen radiological score
PN
(7i = 28)
10:18
64±8
11.4 ±5.7
n = 6
/ t - 7
45 ±32
65 ± 17*»*
n = 21*
n= 13
11.9± 1.4***
53±28"*'
41 ±38
228 ± 276
345 ± 809
166±50
171 ±75
80 ± 28*****
RA controls
(n - 38)
8:30
60±9
9 ±6.2
n - 4
n - 3
34 ±29
49 ±23
n = 17
n - 10
13.3 ± 1.8
28 ±25
35 ±64
166 ± 274
261 ±730
142 ± 33
157 ± 125
44±30
•/><0.05, •*P<0.01, ***P< 0.005, ••••/»< 0.001, ••••
0.0005.
clinic between January and October 1994, were
assessed for the presence of PN. The diagnosis was
supported by nerve conduction studies. Patients had
their neurological symptoms and signs assessed by the
neuropathy symptom score (NSS) and the neurologic
disability score (NDS), respectively [16]. The NSS is
derived from a neurological history that is obtained in
a standard way. Selected symptoms which occur in
neuropathy are scored as present (1) or absent (0), with
the total score being a summation of weakness, sensory
and autonomic symptoms. The NDS is a measure of
neurological deficit and includes cranial nerve
evaluation, strength, deep tendon reflexes and sensory
subsets. The strength is scored from (0) for normal
power to (4) for complete weakness, while reflexes and
sensation are scored (0) for normal, (1) for decreased
and (2) for absent responses. Thirty-eight consecutive
RA patients without clinical symptoms or signs of PN,
as judged by the NSS and the NDS, and 20 healthy
volunteers (HV), were recruited as controls. None of
the controls declined.
The following measures of RA disease activity and
damage were recorded: duration of early morning
stiffness, Ritchie articular index, 10 cm visual analogue
scale for pain, presence of lower limb operations and
extra-articular manifestations, and past or present
medications with disease-modifying therapy.
Of the 28 patients with PN, 13 had extra-articular
manifestations of RA, and of these seven patients had
cutaneous, nail fold vasculitis or vasculitic ulcers on
biopsy, while the remaining six had rheumatoid
pulmonary complications, such as fibrosis, nodules and
pleural effusion. One patient had Felty's syndrome.
Blood was taken for estimation of haemoglobin,
ESR, CRP, IgM RF by ELISA, ANA, ANCA,
cryoglobulins, immunoglobulins, complement, vitamin
B12, folate, creatinine, thyroid-stimulating hormone,
hepatic enzymes, blood glucose and anti-ganglioside
antibodies. A standard chest radiograph was
performed, and hands and feet films were graded by the
Larsen score.
Patients with compression neuropathy or who had
an alternative cause for PN, e.g. metabolic, infective,
toxic or hereditary, were excluded. Four RA patients
with diabetes and alcohol abuse were excluded.
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Fio. 1.—Serum levels of IgG anti-sulphatide antibodies in patients with rheumatoid arthritis and peripheral neuropathy (PN), rheumatoid
arthritis without peripheral neuropathy (RA) and normals (values shown are in arbitrary units). Values > 2 S.D. of the mean for the RA controls
were considered abnormal. mean for the RA controls + 2 S.D.; — mean for the PN, RA, normals.
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FIG. 2.—Serum levels of IgM anti-sulphatide antibodies in patients with rheumatoid arthritis and peripheral neuropathy (PN), rheumatoid
arthritis without peripheral neuropathy (RA) and normals (values shown are in arbitrary units). Values >2 S.D. of the mean for the RA controls
were considered abnormal. mean for the RA controls + 2s.D.; — mean for the PN, RA, normals.
Enzyme-linked immunosorbent assay (ELISA)
A previously described technique was modified [17].
Commercially available (Sigma) bovine gangliosides
GM1 and sulpha tide were added to plastic microtitre
plates at a concentration of 1 /ig/ml in ethanol. After
allowing ethanol to evaporate overnight at 4°C, the
plate was washed with phosphate-buffered saline
(PBS)/0.05% Tween and blocked by 0.1% human
serum albumin in PBS/Tween for 1 h. Each patient
serum diluted 1:100 in PBS/Tween was added to
duplicate wells and incubated for 2 h at room
temperature. PBS/Tween alone was added to
blank wells. A high and low control serum sample
was incubated in each plate. After washing, alkaline
phosphatase-conjugated anti-human IgG or IgM
(1:1000 in PBS/Tween+1% goat serum) was
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FIG. 3.—Serum levels of IgG anti-GMl antibodies in patients with rheumatoid arthritis and peripheral neuropathy (PN), rheumatoid arthritis
without peripheral neuropathy (RA) and normals (values shown are in arbitrary units). Values > 2 s.D. of the mean for the RA controls were
considered abnormal. mean for the RA controls + 2 S.D.; — mean for the PN, RA, normals.
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FIG. 4.—Serum levels of IgM anti-GMl antibodies in patients with rheumatoid arthritis and peripheral neuropathy (PN), rheumatoid arthritis
without peripheral neuropathy (RA) and normals (values shown are in arbitrary units). Values > 2 S.D. of the mean for the RA controls were
considered abnormal. mean for the RA controls + 2 S.D.; — mean for the PN, RA, normals.
added at 100 ^ I/well for 1 h at room temperature. The
plate was washed and incubated with 100/xl/well of
1 mg/ml p-nitrophenyl phosphate in diethanolamine
buffer (Sigma) for 2 h (GM1) or 30 min (sulphatide) at
room temperature.
A total of 50 /il of 3 M NaOH was added to each well
to stop the reaction. The absorbance or optical density
(OD) was read at 405 nm by an ELISA plate reader
(Titertek Multiskan Plus MK.11). A reference serum
with high levels of antibodies was used to obtain a
standard curve from which arbitrary units were
determined. Values greater than two standard devi-
ations of the mean for the RA control patients were
considered to be abnormal. The intra- and interassay
coefficients of variation were between 7.1 and 9.5% and
8.9 and 13.9%, respectively, for the four assays.
Absorption of sera with sulphatide
To test for any cross-reactivity between antibodies to
sulphatide and GM1, diluted sera (1:100) from 20 RA
patients with PN were incubated overnight with or
without 100^g/ml sulphatide in PBS/Tween.
An ELISA was then performed, as described above,
to determine levels of IgM GM1 antibodies with and
without sulphatide absorption.
The percentage of antibody activity remaining after
absorption was calculated as follows:
OD (serum + sulphatide) - OD (blank)
 ] n n
OD (serum only) - OD (blank) x 1UU
Statistical analysis
The significance of differences between the neuro-
pathy and control groups was tested by the
Mann-Whitney (/-test and correlations by Spearman's
rank correlation.
RESULTS
Twenty-eight patients with PN were compared with
the RA control group (Table I). The neuropathic group
had a higher pain score (P < 0.005), more extra-
articular features (P < 0.05), higher erosive scores
(/•< 0.0001), lower haemoglobin (P < 0.005), higher
ESR (P < 0.001) and were more frequently on
disease-modifying drugs (P < 0.05). However, age, RA
disease duration, lower limb operations, early morning
stiffness, CRP, rheumatoid factor, ANA and
complement levels were not significantly different
between the neuropathic group and their RA controls.
RA patients with PN had significantly higher IgG
anti-sulphatide antibody levels than RA controls
(P< 0.005) and HV (P < 0.0001). Levels of IgM
anti-sulphatide antibodies were also raised among RA
neuropathy patients compared to RA controls
CP<0.05) and HV (P < 0.001). IgG anti-GMl
antibody levels were significantly higher in the
neuropathic group than in the HV (P < 0.0001), but
were not significantly greater than those in RA controls
(P = 0.09). There were no statistical differences
between the three groups of patients for IgM anti-GM 1
antibody levels, although the neuropathic group had a
higher mean value.
Twelve patients (43%) with RA and PN compared
to two patients (5%) from the RA control group had
abnormal antibody levels against one or more
gangliosides (P < 0.001), but none of the healthy
volunteers had elevated levels, according to criteria
used in this study (Figs 1-4). Seven patients with RA
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FIG. 5.—Correlation (r = 0.55, P < 0.005) between IgM anti-GMl and the neurologic disability score.
and PN had abnormal antibody levels against more
than one ganglioside.
There were significant correlations between IgM
anti-GMl and IgM anti-sulphatide antibodies
(P < 0.0005), and between IgM anti-GMl and IgG
anti-sulphatide antibodies (P < 0.0001). Four of 20
sera (20%) from RA patients with PN absorbed with
sulphatide demonstrated a ^50% reduction in IgM
anti-GMl antibody levels. However, the majority of
sera (65%) showed little change (<5%) in IgM GM1
binding.
Those patients who demonstrated high anti-
ganglioside antibody levels had lower C4 complement
levels (P < 0.05). There was no significant correlation
between the anti-ganglioside antibody levels and
rheumatoid factor, and measures of RA disease activity
or damage. Four patients with PN and elevated levels
of anti-ganglioside antibodies had clinical evidence of
vasculitis.
Neurophysiological studies revealed axonal poly-
neuropathy and mononeuritis multiplex in 10 (36%)
patients. Clinical sensorimotor neuropathy was found
in 23 patients (82%), while pure motor or sensory
neuropathy was observed in two (7%) and three (11%)
patients, respectively. The NDS correlated with RA
duration (P < 0.05), and with the presence of IgM
GM1 (P< 0.005) (Fig. 5) and IgM sulphatide
(P < 0.05) antibodies.
DISCUSSION
We have demonstrated that a significant proportion
of RA patients with PN (43%) had abnormal
anti-ganglioside antibody levels. In contrast, only 5%
of RA patients without PN had elevated levels, while
only low levels were found in sera of healthy
volunteers. We found that PN occurs more frequently
in patients with severe RA, which is in agreement with
other studies [18].
We did not find a relationship between the
anti-ganglioside antibodies tested and a clinical subset
of neuropathy. This is explained by the majority of
patients having a mixed sensorimotor presentation,
and only a small number of patients having a pure
motor or sensory neuropathy. Similarly, we are not
able to relate the presence of the anti-gangliosides to
axonal or demyelination changes because of the smaller
number of patients with pure axonal features.
The presence of PN in patients with RA can be
difficult to recognize as patients often relate neuro-
logical symptoms to joint disease. It is also difficult to
assess the neurological system in the presence of severe
joint disease. In this study, we used the NDS for the
purpose of assessing severity and quantitating
neurological deficit. Because the NDS is a global score
of muscle weakness, reflex and sensory abnormality, it
is thought to be one of the more robust measures of
global neurological deficit, and its usefulness has been
demonstrated in a trial of plasma exchange in patients
with chronic inflammatory demyelinating polyneuro-
pathy [19]. The sensitivity and reproducibility of NDS
are established [20, 21].
In our study, the presence of rheumatoid factor was
not different in patients with and without PN, which
suggests that it is not an important factor in the
aetiology of neuropathy. There was evidence of
complement C4 consumption in those neuropathy
patients with high anti-ganglioside antibodies,
suggesting that complement activation may play a
pathogenic role.
Antibodies may be pathogenic or arise as a result of
non-specific damage to neuronal tissues. It is not clear
why patients with RA complicated by PN develop
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antibodies against gangliosides. It could relate to
failure of tolerance by peripheral T cells or be a result
of molecular mimicry, as the ganglioside carbohydrate
sequence is shared with bacterial lipopolysaccharide
[22]. However, greater neurological deficit, as measured
by the NDS, in those patients with higher anti-IgM
antibodies against GM1 and sulphatide molecules,
indicates that these antibodies in RA PN are partly
related to the severity of neuronal tissue breakdown.
Other clinical syndromes have been associated with
denned anti-ganglioside specificity. IgM anti-GMl
antibodies are found in 60-80% of patients with
multifocal motor neuropathy [23] and IgM anti-sul-
phatide antibodies have been described in chronic
axonal sensory neuropathy [24], while IgG anti-GQlb
antibodies are detected in patients with Miller Fisher
syndrome [25]. In the present study, seven of the 12
patients (58%) with anti-ganglioside antibodies had
antibodies to both gangliosides, with significant
correlations between the IgM and IgG antibodies to
both gangliosides. The absorption experiments
confirmed IgM cross-reactivity with both gangliosides
in only 20% of the sera tested. This suggests that in the
majority of patients clones of activated B cells are
present which may produce antibodies to different
gangliosides. These observations are in agreement with
a previous study of patients suffering from lower motor
neuron syndromes where there was only limited
cross-reactivity with different gangliosides [26].
In conclusion, measurement of anti-ganglioside
antibodies may prove to be helpful in the detection and
assessment of PN in RA. Further work is needed to
determine the pathogenicity of these antibodies and
their relationship with the progression of neuronal
pathology.
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